PLAUR and cancer: [64Cu]Cu-uPAR-PET with [64Cu]Cu-DOTA-AE105 has only been evaluated in preclinical models in different cancers and in one phase I clinical trial in patients with breast, prostate, and lung cancer [24, 25] but never in head and neck cancer patients nor preclinical models that closely resembles OSCC tissue characteristics.